MASLD: The New Name for Fatty Liver Disease and What the Renaming Changes

The letter from the clinic looked ordinary until one line stopped a reader cold: “ultrasound consistent with MASLD.” She had been told, years earlier, that she had “a bit of fatty liver.” Now the diagnosis had a new name, five capital letters, and no explanation. Her search history that evening is why this article exists.

As of early 2026, MASLD is one of the fastest-rising liver terms in search, and the timing is not accidental. In June 2023 an international panel formally retired “nonalcoholic fatty liver disease” and replaced it with metabolic dysfunction-associated steatotic liver disease. Then came something the field had waited decades for: in March 2024 the first medicine for the inflammatory form of the condition received US approval, and in August 2025 a second followed. Lab reports, clinic letters and headlines switched vocabulary almost overnight.

If you are holding one of those letters, this explainer is for you. It covers what the new name means, what the renaming genuinely changes for diagnosis and care, and where the evidence is solid, promising or still thin.

What changed recently: from NAFLD to MASLD, then the first approved medicines

Three dates explain the surge of interest. The first is June 2023, when a Delphi consensus (a formal process in which experts vote in rounds until they agree) involving 236 panelists from 56 countries, convened by the major American, European and Latin American liver societies, voted to replace “nonalcoholic fatty liver disease” with MASLD. The same statement renamed NASH, the inflammatory form, as MASH, and created an umbrella term, steatotic liver disease, with a new middle category for people who have both metabolic risk factors and higher alcohol intake.

The second date is March 2024. The US Food and Drug Administration granted accelerated approval to resmetirom (Rezdiffra) for adults with noncirrhotic MASH and moderate to advanced liver scarring. It was the first medicine approved specifically for this disease, more than four decades after the term NASH was coined in 1980.

The third is August 2025, when semaglutide (Wegovy), a GLP-1 receptor agonist already prescribed for type 2 diabetes and weight management, received accelerated approval for the same group of patients. Accelerated approval means a medicine is cleared on the strength of a surrogate marker, in this case improvement on liver biopsy, while longer trials continue to test whether it prevents cirrhosis, liver failure or death.

Two practical shifts followed. Imaging reports and clinic letters began using “steatotic” and “MASLD,” which is why many readers are meeting the word without an explanation. And liver societies now encourage primary care clinicians to check people with type 2 diabetes, or obesity plus other risk factors, for liver scarring using a simple blood-test score, rather than waiting for symptoms that may never come.

What is MASLD (metabolic dysfunction-associated steatotic liver disease)?

Start with the word in the middle. Steatosis means fat stored inside liver cells; a liver is considered steatotic when fat is present in more than about 5 percent of those cells, measured by biopsy or estimated by imaging. A healthy liver holds very little fat, so this threshold marks the point at which storage becomes abnormal.

MASLD is steatosis occurring in a person with at least one feature of metabolic dysfunction, which is the body’s reduced ability to handle sugar, fat and energy, most often driven by insulin resistance. The 2023 consensus defined five such features:

• Excess body weight: a body mass index of 25 or above (23 or above in people of Asian ancestry), or a waist circumference above sex- and ethnicity-specific cutoffs.
• Raised blood sugar: fasting glucose of 100 mg/dL or higher, an HbA1c of 5.7 percent or higher, or diagnosed type 2 diabetes.
• Blood pressure of 130/85 mm Hg or higher, or treatment for high blood pressure.
• Triglycerides of 150 mg/dL or higher, or treatment for high triglycerides.
• Low HDL cholesterol, below 40 mg/dL in men or 50 mg/dL in women, or lipid-lowering treatment.

Only one is required. The diagnosis also assumes alcohol is not the main driver: current intake below roughly 140 grams a week for women and 210 grams for men, which is about ten and fifteen standard US drinks respectively. Other specific causes, such as certain medicines or rare genetic disorders, are classified separately.

Put simply, MASLD is a liver condition defined by what is present in the rest of the body, not by what is absent from a person’s drinking history. That shift sounds subtle and turns out to matter a great deal.

NAFLD vs MASLD: what the renaming actually changes

The question people search most often is also the fairest one: is this a different disease, or the same disease with a new label? The honest answer is mostly the latter, with three changes that matter.

First, the logic of diagnosis flipped. NAFLD was a diagnosis of exclusion: fat in the liver, not much alcohol, no other identifiable cause. MASLD is a diagnosis of inclusion. A clinician looks for a positive reason the fat is there, and that reason is one or more cardiometabolic risk factors. Large cohort comparisons found that around 98 to 99 percent of people who met the old NAFLD criteria also meet MASLD criteria, which is why decades of NAFLD research still apply.

Second, the new system stopped forcing a choice between metabolic disease and alcohol. Under NAFLD, a person with obesity and diabetes who also drank moderately heavily fell into a gray zone. MetALD now describes that group explicitly, and alcohol intake is recorded as a sliding scale rather than a yes-or-no gate.

Third, the vocabulary changed on purpose. The panel judged “fatty” stigmatizing and “nonalcoholic” misleading, since many people assumed a condition with “alcoholic” in its name implied drinking. In the surveys that informed the vote, a majority of patients and clinicians agreed the old name carried stigma that could delay care.

What did not change: the biology, the staging of scarring, the central role of fibrosis in predicting outcomes, or the core treatment advice. If you were told you had NAFLD, you almost certainly have MASLD, and nothing about your liver changed with the name.

Steatotic liver disease: the full family tree, including MetALD

The 2023 statement did something broader than a rename. It created a top-level term, steatotic liver disease (SLD), for any liver with excess fat, then sorted the causes beneath it. The table summarizes the categories as the consensus defined them.

Category	What defines it	Weekly alcohol intake
MASLD	Steatosis plus at least one cardiometabolic risk factor	Below 140 g (women) or 210 g (men)
MetALD	Meets MASLD criteria and drinks above the MASLD threshold	140–350 g (women) or 210–420 g (men)
Alcohol-related liver disease (ALD)	Alcohol is the dominant cause	Above 350 g (women) or 420 g (men)
Specific-cause SLD	Fat due to an identified cause such as certain medicines, hepatitis C or rare metabolic disorders	Any
Cryptogenic SLD	Steatosis with no cardiometabolic risk factor and no other cause found	Below MASLD threshold

Two points deserve emphasis. MetALD is the category clinicians most welcomed. Alcohol and metabolic dysfunction do not simply add their harms; they appear to multiply them, and the old binary made that interaction invisible in records and research. A person in this group benefits from attention to both drivers at once.

Cryptogenic SLD is deliberately small. If someone has liver fat and no risk factors, clinicians are encouraged to keep looking, including for conditions that mimic metabolic steatosis. Some people in this group are later found to have a cardiometabolic feature missed at first assessment.

For most readers the practical takeaway is simple: your category depends on two things, your metabolic health and an honest estimate of how much you drink. Both are worth discussing openly, because both change what monitoring looks like.

How common is MASLD and who is most at risk?

If the numbers feel implausible, that is because the condition is so quiet. Pooled analyses estimate that about 30 percent of adults worldwide have MASLD, up from roughly a quarter two decades ago. US federal estimates place the figure at around 24 percent of adults, about one in four, with the inflammatory form, MASH, affecting an estimated 1.5 to 6.5 percent.

Risk climbs steeply with metabolic disease. Among people with type 2 diabetes, studies find liver fat in roughly 55 to 70 percent, and a substantial minority already have significant scarring when first checked. Obesity carries similar odds; in people living with severe obesity, prevalence approaches 90 percent in some series. Age, high triglycerides and high blood pressure each raise the likelihood further.

Not everyone with MASLD carries excess weight. “Lean MASLD,” the term for the condition in people with a body mass index in the normal range, accounts for roughly 10 to 20 percent of cases in many populations and a larger share in parts of Asia. These individuals usually still have insulin resistance, a larger waist relative to their frame, or fat concentrated around internal organs. Lean MASLD is not a milder version; some cohorts show comparable or higher rates of advanced disease, possibly because it is detected late.

Genetics matters too. A common variant in a gene called PNPLA3, which influences how liver cells handle fat droplets, roughly doubles the risk of progressive disease in carriers and is more frequent in people of Hispanic ancestry. Children are not spared: MASLD is now the most common chronic liver condition among US adolescents, tracking the rise in childhood obesity.

Fatty liver symptoms: what MASLD actually feels like

Here is the uncomfortable truth behind so many accidental diagnoses: most people with MASLD feel nothing. The liver has no pain receptors within its tissue, and fat accumulation does not stretch the organ’s outer capsule in a way most people notice. The typical discovery is an ultrasound ordered for suspected gallstones, or liver enzymes flagged on a routine blood panel.

When symptoms do appear, they are vague. Tiredness that does not track with sleep is the most reported. Some people describe a dull ache or sense of fullness under the right ribs, where the liver sits, especially after large meals. Neither symptom is specific, and both are at least as likely to come from something else.

Two search questions deserve direct answers. Can fatty liver cause stomach pain? Rarely, and usually only as mild right-sided discomfort rather than true stomach pain; sharp, severe or persistent abdominal pain should prompt a medical review for other causes such as gallbladder disease or an ulcer. What are the signs of grade 2 fatty liver? Grades describe how much fat is present on imaging or biopsy (grade 2 means roughly a third to two thirds of liver cells contain fat), not how a person feels. Most people with grade 2 steatosis have no symptoms, and the grade says nothing about scarring, which is what determines long-term risk.

Signs that tend to arrive only with advanced scarring include yellowing of the skin or eyes, swelling of the abdomen or legs, easy bruising, spider-like blood vessels on the chest, and confusion. These are late signs, not early warnings, which is exactly why clinicians now prefer to test risk rather than wait for symptoms.

How MASLD is diagnosed: grades, stages and the tests behind them

Diagnosis has two jobs: confirm the fat is there, and estimate how much scarring has developed. Only the second predicts what happens next.

Fat is usually found on ultrasound, which detects steatosis once it is moderate but can miss milder cases. A measurement called controlled attenuation parameter, taken during a vibration-based scan, quantifies fat more precisely, and MRI-based fat fraction is the most accurate noninvasive method, used mostly in research.

Scarring, or fibrosis, is staged from F0 (none) to F4 (cirrhosis, in which scar tissue has reorganized the liver). Clinicians increasingly begin with FIB-4, a score calculated from age, two liver enzymes (ALT and AST) and platelet count, all of which appear on routine blood tests. A low FIB-4 makes advanced scarring unlikely and often means repeating the test every year or two; a higher score prompts a second-line test, typically transient elastography, which measures liver stiffness with a painless pulse through the skin. Stiffer tissue means more scar.

Liver enzymes alone are poor guides. Up to half of people with significant fibrosis have ALT in the normal range, which is why “your liver tests are fine” is not the same as “your liver is fine.”

Biopsy, once the gold standard, is now reserved for unclear cases or clinical trials. It samples a tiny sliver of the organ, carries a small risk of bleeding, and is not something most people with MASLD will ever need.

Keep the two vocabularies separate when reading a report. “Grade” refers to fat and inflammation; “stage” refers to scar. Grade 2 steatosis with F1 fibrosis describes a very different situation from grade 1 with F3, and the second deserves far closer follow-up.

MASH vs NASH: when fat turns into inflammation and scarring

MASH and NASH are the same condition under two names: the inflammatory stage of steatotic liver disease, in which fat-laden liver cells become injured, swell (a change pathologists call ballooning) and attract immune cells. Because inflammation repeatedly damages and repairs tissue, it lays down scar, and scar is what carries a liver toward cirrhosis.

Not everyone travels that road. Of people with MASLD, roughly 20 to 30 percent have MASH at any one time, and of those, a smaller fraction develop progressive fibrosis. Progression is slow, on average about one fibrosis stage every seven years in MASH, but uneven: some people stall for decades while others, often with diabetes, advance faster. The disease can also move backward; paired-biopsy studies show fibrosis regressing when metabolic health improves.

Why does stage matter so much? Long-term cohorts show that the risk of liver-related death, liver cancer and need for transplant rises sharply once fibrosis reaches F3, and that fibrosis stage predicts outcomes far better than the amount of fat or enzyme levels. This is why both newly approved medicines are indicated for MASH at stages F2 and F3: enough scarring to carry real risk, but not yet cirrhosis.

Hepatocellular carcinoma, the main form of liver cancer, is a recognized complication. It is far more likely in cirrhosis, though it can occasionally occur before that stage in MASH, and people with MASLD-related cirrhosis are usually offered ultrasound surveillance every six months. Those surveillance decisions are individual and belong with the treating liver specialist.

The practical message of the MASH versus NASH debate is that the name is cosmetic and the stage is everything.

What the evidence actually says about MASLD, graded

Evidence in liver disease comes in layers, and a reader deserves to know which layer each claim sits on. Randomized controlled trials (RCTs), in which participants are assigned by chance to a treatment or comparison, are the strongest. Observational studies follow people without assigning treatment; they show associations but cannot prove cause. Expert opinion fills the gaps.

Weight reduction: strong. Multiple RCTs and a landmark paired-biopsy study show that losing 3 to 5 percent of body weight reduces liver fat, 7 percent or more resolves inflammation in most participants, and 10 percent or more is associated with fibrosis regression in a majority. The dose-response pattern is consistent across studies.

Mediterranean-style eating: moderate. Several RCTs show reduced liver fat even with stable weight, though trials are small and short. Exercise without weight loss: moderate, with RCTs showing modest fat reduction from both aerobic and resistance training.

Coffee: observational only. Large cohorts consistently link regular coffee drinking with less fibrosis, but no trial has tested it, so the finding supports reassurance rather than prescription.

Resmetirom and semaglutide: strong for liver histology, pending for hard outcomes. Both have phase 3 RCTs with biopsy-proven improvement in MASH and fibrosis at roughly one year or more. Whether they reduce cirrhosis, liver failure or death is still being measured, and continued approval depends on those results.

Vitamin E and pioglitazone: moderate, from RCTs in people without and with diabetes respectively, but neither is approved for MASH, and any use is a specialist decision weighing individual risks.

Herbal “liver detox” products, milk thistle and most supplements: weak to none. Trials are small and inconsistent, and some botanicals have caused liver injury.

What foods are good for liver repair? What the diet trials show

“Liver repair” is a phrase the internet loves and hepatologists approach carefully. The liver does regenerate, and liver fat can fall substantially within weeks of dietary change, but no single food has been shown to reverse scarring. What the trials support is a pattern, not a superfood.

The pattern with the best evidence is Mediterranean-style eating: vegetables, legumes, whole grains, nuts, fish, and olive oil as the main fat, with little red or processed meat and few sweets. In randomized trials this approach lowered liver fat measured by MRI by roughly a third over several months, in some cases without weight change. The mechanisms are plausible: fiber slows sugar absorption, unsaturated fats improve insulin signaling, and plant polyphenols appear to reduce inflammation.

What to cut matters as much as what to add. Sugar-sweetened drinks are the most consistent dietary predictor of liver fat in observational studies, likely because fructose is processed almost entirely by the liver and readily converted to fat. Ultra-processed foods, refined starches and oversized portions of any kind feed the same pathway.

Coffee, as noted above, is associated with less fibrosis in cohort studies; there is no reason for most people with MASLD to give it up, and unsweetened preparations avoid adding sugar.

Alcohol has no safe amount once liver scarring is present. Even intake below the MASLD threshold adds measurable risk when fibrosis exists, which is why many specialists recommend abstaining if elastography shows significant stiffness.

A final caution: supplements marketed for liver health have little trial support, and concentrated herbal products such as green tea extract have caused serious liver injury. Food, eaten as a pattern over months, is the intervention with the evidence.

Medicines now approved for MASH: resmetirom and semaglutide

For decades the honest answer to “is there a pill for this” was no. That changed twice in 18 months, and both approvals share the same boundaries: adults with MASH and moderate to advanced fibrosis (F2 to F3) but not cirrhosis, alongside diet and exercise rather than instead of them.

Resmetirom (Rezdiffra) is a thyroid hormone receptor-beta agonist, meaning it selectively stimulates a thyroid hormone receptor concentrated in the liver, increasing fat breakdown there without body-wide thyroid effects. In its phase 3 trial of nearly 1,000 participants, around a quarter of those treated had MASH resolve on repeat biopsy at one year, compared with about 10 percent on placebo, and a similar proportion saw fibrosis improve by at least one stage versus about 14 percent on placebo. Diarrhea and nausea were the most common side effects, mostly early and mild.

Semaglutide (Wegovy) is a GLP-1 receptor agonist, which mimics a gut hormone that improves insulin release, slows stomach emptying and reduces appetite. In its phase 3 MASH trial, roughly 63 percent of treated participants had MASH resolve without worsening fibrosis at 72 weeks, against about 34 percent on placebo, and about 37 percent had fibrosis improve versus around 22 percent. Gastrointestinal effects were again the most frequent.

Both are accelerated approvals. Confirmatory data on cirrhosis, transplant and death are expected over the coming years, and both labels may change as results arrive. Neither is approved for people with cirrhosis or for MASLD without significant fibrosis.

Whether either medicine suits a particular person, and how it is used, is a decision for the prescribing clinician, who weighs fibrosis stage, other conditions and existing prescriptions. This article names them so readers recognize them in the news, not as a recommendation.

Why MASLD sits in heart and metabolism, not just the liver clinic

A reader who learns they have MASLD often asks first about liver failure. The data point somewhere else. In long-term cohorts, the leading cause of death among people with MASLD is cardiovascular disease, not liver disease, and the gap is wide at every stage short of advanced fibrosis.

The reason is shared plumbing. Insulin resistance, the underlying driver of MASLD, also raises triglycerides, lowers HDL cholesterol, pushes blood pressure upward and promotes inflammation in artery walls. A steatotic liver releases more very-low-density lipoprotein, the particle that carries triglycerides, and more inflammatory signals into the bloodstream. Meta-analyses of observational studies associate MASLD with roughly a 50 to 60 percent higher risk of heart attack and stroke after accounting for conventional risk factors, along with higher rates of atrial fibrillation and heart failure with preserved pumping function.

That connection changes priorities. Guidance from liver and cardiology bodies now treats a MASLD diagnosis as a prompt to check blood pressure, lipids and glucose and to manage them to standard targets. Statins, which some patients fear will harm the liver, are considered safe in MASLD and in compensated cirrhosis according to observational data and guideline statements, and people who need them for cardiovascular reasons are generally advised to continue. Any change to an existing prescription belongs with the clinician who wrote it.

The screening runs in reverse as well. Liver societies recommend that people with type 2 diabetes, or with obesity plus another metabolic risk factor, have a FIB-4 score calculated periodically even with normal enzymes, because this is where advanced fibrosis hides.

In other words, the renaming did more than swap words. It relocated the condition into the whole metabolic picture, which is where its risks actually live.

Common myths about MASLD, corrected

Viral claims about fatty liver travel faster than the evidence. Five deserve a plain correction.

“Only heavy drinkers get fatty liver.” False, and this misconception is one reason the name was changed. MASLD by definition occurs in people drinking little or no alcohol; roughly one in four US adults has it, and most do not drink heavily. Alcohol-related liver disease is a separate category with its own criteria.

“Normal liver tests mean a healthy liver.” Not reliably. Up to half of people with advanced fibrosis have ALT within the normal range. Fibrosis scores and elastography, not enzymes alone, are how risk is assessed, which is why guidelines now recommend FIB-4 in high-risk groups regardless of enzyme results.

“A detox or cleanse flushes fat from the liver.” No trial supports this. The liver clears toxins on its own; the way to reduce liver fat is sustained change in energy balance and diet quality. Several “cleanse” products have themselves caused liver injury severe enough to require hospital care.

“Thin people cannot have it.” Lean MASLD represents an estimated 10 to 20 percent of cases and can be just as advanced. Waist size, blood sugar and lipid levels matter more than the number on the scale.

“MASLD is just rebranding with no medical meaning.” The biology is unchanged, but the new definition requires clinicians to look for and record metabolic drivers, created a category for combined metabolic and alcohol-related disease, and removed language that surveys showed deterred people from seeking care.

A useful habit when meeting any new claim: ask whether it rests on a randomized trial, an observational association, or a testimonial. Most viral liver advice sits firmly in the third category.

When to see a doctor about MASLD

Because MASLD is silent, the decision to seek care rests more on risk than on symptoms. Two situations warrant an unhurried appointment and a conversation about a FIB-4 score: you have type 2 diabetes or prediabetes, or you carry excess weight along with high blood pressure, high triglycerides or low HDL cholesterol. The same applies if an imaging report mentions steatosis, fatty infiltration or MASLD and no one has explained what follows.

Other reasons for a routine visit include persistent unexplained fatigue, a dull ache under the right ribs lasting more than a couple of weeks, a family history of cirrhosis or liver cancer, or a liver enzyme result flagged as abnormal on any blood test.

Some signs are red flags and need same-day medical attention or emergency care:

• Yellowing of the skin or the whites of the eyes.
• Vomiting blood or passing black, tar-like stools, which can signal bleeding from swollen veins in the esophagus.
• New or rapid swelling of the abdomen, or sudden swelling of both legs.
• Confusion, unusual drowsiness or personality change, which can indicate toxins the liver is no longer clearing.
• Severe or worsening pain in the upper right abdomen, especially with fever.
• Unexplained weight loss or easy, widespread bruising.

If you take any prescribed medicine, including a statin, a diabetes drug or one of the newer MASH treatments, and you notice new side effects or wonder whether it is right for your liver, raise it with the clinician who prescribed it rather than stopping on your own. Abruptly stopping some medicines carries its own risks.

Bring to the appointment a realistic estimate of weekly alcohol intake, recent blood results, any imaging reports and a list of supplements, since several marketed for liver health can affect the liver or interact with prescriptions.

Frequently asked questions

What is nonalcoholic fatty liver disease (NAFLD)?

NAFLD is the former name for fat buildup in the liver in people who drink little or no alcohol and have no other identifiable cause. In 2023 it was renamed MASLD, metabolic dysfunction-associated steatotic liver disease, to reflect that the fat is driven by metabolic factors such as insulin resistance, excess weight or diabetes. Nearly everyone previously diagnosed with NAFLD meets the new MASLD criteria.

Can fatty liver cause stomach pain?

Usually not. MASLD is painless in most people because the liver’s tissue has no pain receptors. Some describe a dull ache or fullness under the right ribs, where the liver sits, but true stomach pain is uncommon. Sharp, severe or persistent abdominal pain should be assessed for other causes such as gallstones, an ulcer or pancreatitis rather than attributed to fatty liver.

What are the signs and symptoms of grade 2 fatty liver disease?

Most people with grade 2 steatosis have no symptoms at all. The grade describes how much fat is seen on imaging or biopsy, roughly a third to two thirds of liver cells, not how someone feels or how much scarring exists. Fatigue or mild right-sided discomfort can occur but are nonspecific. What matters for long-term risk is the fibrosis stage, which needs separate testing.

What foods are good for liver repair?

No single food repairs the liver, but a Mediterranean-style pattern has the best trial evidence for reducing liver fat: vegetables, legumes, whole grains, nuts, fish and olive oil, with little red or processed meat. Cutting sugar-sweetened drinks and ultra-processed foods matters as much as adding anything. Coffee is linked to less fibrosis in observational studies, while herbal liver supplements lack evidence and some have caused harm.

MASH vs NASH: is there any medical difference?

No. MASH (metabolic dysfunction-associated steatohepatitis) is simply the 2023 name for NASH (nonalcoholic steatohepatitis). Both describe the inflammatory form of steatotic liver disease in which injured, fat-filled liver cells trigger inflammation and scarring. The diagnostic criteria for the metabolic component changed slightly with the renaming, but the biology, staging and treatment approach are identical, and research on NASH still applies.

Can MASLD be reversed?

Liver fat and early scarring can regress. Paired-biopsy studies show that losing about 7 percent of body weight resolves inflammation in most people, and 10 percent or more is associated with fibrosis improvement in a majority. Advanced cirrhosis is far less likely to regress, which is why early detection matters. Progress is measured with repeat blood scores or elastography rather than by symptoms, which are usually absent.

Can I drink alcohol if I have MASLD?

The MASLD definition allows low intake, below about 140 grams a week for women and 210 for men, but the evidence suggests alcohol and metabolic dysfunction multiply each other’s harm. Once significant fibrosis is present, many liver specialists recommend abstaining entirely, because even modest intake adds measurable risk. Discuss your actual intake honestly with your clinician, since it also determines whether you fall into the MetALD category.

Can children and teenagers have MASLD?

Yes. MASLD is now the most common chronic liver condition in US adolescents, closely tracking childhood obesity and type 2 diabetes. It is usually silent and found on blood tests or ultrasound. Pediatric guidance focuses on family-based changes in diet and physical activity, and the newly approved MASH medicines are authorized for adults only. Concerns about a child’s liver tests belong with their pediatrician.

Can a thin person have MASLD?

Yes. Lean MASLD, in people with a body mass index in the normal range, makes up roughly 10 to 20 percent of cases in many populations and more in parts of Asia. These individuals typically still have insulin resistance, a larger waist relative to their frame, or fat concentrated around internal organs. Lean MASLD is not milder; some studies show comparable rates of advanced fibrosis, possibly because it is diagnosed later.

How often should MASLD be monitored?

Monitoring depends on fibrosis risk, not symptoms. A low FIB-4 score typically means repeating it every one to two years, or more often in people with diabetes. A higher score prompts elastography and, if stiffness is raised, referral to a liver specialist for closer follow-up. People with cirrhosis are usually offered ultrasound surveillance every six months. Your clinician sets the schedule based on your results.

References

• MedlinePlus: Fatty Liver Disease
• NIH NIDDK: Nonalcoholic Fatty Liver Disease (NAFLD) and NASH
• Cleveland Clinic: Fatty (Steatotic) Liver Disease
• NHS: Non-alcoholic fatty liver disease (NAFLD)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.